Core Viewpoint - Zhendong Pharmaceutical is enhancing its focus on allergy emergency medications by introducing an innovative epinephrine nasal spray formulation, addressing the limitations of traditional epinephrine injections [1][2]. Group 1: Market Opportunity - There are approximately 240 million patients with allergic rhinitis in China, with food allergy rates among children under one year old ranging from 6% to 8%, indicating a growing patient population [1]. - The global epinephrine market reached $5 billion in 2020, with the auto-injector segment accounting for 93.3% of the market share, reflecting a compound annual growth rate (CAGR) of 18% over five years [1]. Group 2: Product Development - Zhendong Pharmaceutical's nasal spray is based on years of formulation technology development and aims to provide a more user-friendly alternative to traditional epinephrine delivery methods [2][3]. - The new nasal spray formulation is designed to have higher bioavailability, faster absorption rates, and less local irritation compared to existing nasal delivery technologies, outperforming similar products already on the market [2]. Group 3: Regulatory and Patent Strategy - The product is currently undergoing preclinical research, with core patents already filed in major markets including China, the US, Europe, Japan, and South Korea, covering key aspects such as drug composition and preparation processes [3]. - The company plans to accelerate clinical research and registration applications to bring the product to market as soon as possible [3].